{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:05:10Z","timestamp":1776989110931,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006162","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Ci\u00eancia e Tecnologia do Estado de Pernambuco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.imlet.2020.01.004","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T11:21:23Z","timestamp":1579173683000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Sensitivity and specificity of Interleukin 29 in patients with rheumatoid arthritis and other rheumatic diseases"],"prefix":"10.1016","volume":"220","author":[{"given":"Laurindo Ferreira","family":"da Rocha Junior","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Luzia","family":"Branco Pinto Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moacyr Jesus Barreto","family":"de Melo R\u00eago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anderson Rodrigues","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"de Melo Vilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo Deleon","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a","family":"Tavares Dantas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique","family":"de Ata\u00edde Mariz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"da Rocha Pitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira Galdino","family":"da Rocha Pitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2020.01.004_bib0005","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2020.01.004_bib0010","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imlet.2020.01.004_bib0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"Gonzalez-Navajas","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imlet.2020.01.004_bib0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cytogfr.2010.04.002","article-title":"IL-28A, IL-28B, and IL-29: Promising cytokines with type I interferon-like properties","volume":"21","author":"Witte","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.imlet.2020.01.004_bib0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1189\/jlb.1208761","article-title":"Interferon-lambdas: The modulators of antivirus, antitumor, and immune responses","volume":"86","author":"Li","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.imlet.2020.01.004_bib0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.imlet.2020.01.004_bib0035","doi-asserted-by":"crossref","first-page":"32269","DOI":"10.1074\/jbc.M404789200","article-title":"Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29\/interferon-lambda 1: similarities with type I interferon signaling","volume":"279","author":"Dumoutier","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.imlet.2020.01.004_bib0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/ar4445","article-title":"Understanding IFNlambda in rheumatoid arthritis","volume":"16","author":"de Groen","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2020.01.004_bib0045","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.str.2010.02.009","article-title":"Structure and mechanism of receptor sharing by the IL-10R2 common chain","volume":"18","author":"Yoon","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.imlet.2020.01.004_bib0050","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/sj.gene.6364382","article-title":"Human interferon lambda-1 (IFN-lambda1\/IL-29) modulates the Th1\/Th2 response","volume":"8","author":"Jordan","year":"2007","journal-title":"Genes Immun."},{"key":"10.1016\/j.imlet.2020.01.004_bib0055","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2567.2008.02862.x","article-title":"Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro","volume":"125","author":"Srinivas","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.imlet.2020.01.004_bib0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.gene.6364348","article-title":"Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1\/IL-29)","volume":"8","author":"Jordan","year":"2007","journal-title":"Genes Immun."},{"key":"10.1016\/j.imlet.2020.01.004_bib0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000430330","article-title":"IL-29 enhances LPS\/TLR4-Mediated inflammation in rheumatoid arthritis","volume":"37","author":"Xu","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.imlet.2020.01.004_bib0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1620\/tjem.241.89","article-title":"Elevated serum levels of Interleukin-29 are associated with disease activity in rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies","volume":"241","author":"Chang","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.imlet.2020.01.004_bib0075","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.amjmed.2007.04.005","article-title":"Rheumatoid arthritis: diagnosis and management","volume":"120","author":"Majithia","year":"2007","journal-title":"Am. J. Med."},{"key":"10.1016\/j.imlet.2020.01.004_bib0080","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2020.01.004_bib0085","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0697-z","article-title":"Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters","volume":"17","author":"Contreras-Y\u00e1\u00f1ez","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2020.01.004_bib0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.autrev.2012.05.007","article-title":"Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis","volume":"12","author":"Trouw","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.imlet.2020.01.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/545493","article-title":"Cytokines as biomarkers in rheumatoid arthritis","volume":"2014","author":"Burska","year":"2014","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.imlet.2020.01.004_bib0100","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2020.01.004_bib0105","first-page":"581","article-title":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","author":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","year":"1980","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2020.01.004_bib0110","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.1780331101","article-title":"The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand","volume":"33","author":"Altman","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2020.01.004_bib0115","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780290816","article-title":"Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association","author":"Altman","year":"1986","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2020.01.004_bib0120","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780340502","article-title":"The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip","author":"Altman","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2020.01.004_bib0125","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780330203","article-title":"The american college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2020.01.004_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2020.01.004_bib0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2020.01.004_bib0140","doi-asserted-by":"crossref","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","author":"Aletaha","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2020.01.004_bib0145","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.imlet.2020.01.004_bib0150","doi-asserted-by":"crossref","DOI":"10.1186\/ar3363","article-title":"Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity","volume":"13","author":"Wu","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2020.01.004_bib0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/jid.2010.244","article-title":"Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus","volume":"131","author":"Zahn","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.imlet.2020.01.004_bib0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08916934.2015.1054028","article-title":"Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29)","volume":"48","author":"Dantas","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.imlet.2020.01.004_bib0165","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9631510","article-title":"Interleukin-29 enhances synovial inflammation and cartilage degradation in osteoarthritis","volume":"2016","author":"Xu","year":"2016","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.imlet.2020.01.004_bib0170","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1186\/ar4357","article-title":"IL-29 enhances Toll-like receptor-mediated IL-6 and IL-8 production by the synovial fibroblasts from rheumatoid arthritis patients","volume":"15","author":"Xu","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2020.01.004_bib0175","doi-asserted-by":"crossref","DOI":"10.1186\/ar4067","article-title":"Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis","volume":"14","author":"Wang","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2020.01.004_bib0180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12419","article-title":"Autoimmune regulator and self-tolerance \u2013 molecular and clinical aspects","volume":"271","author":"Abramson","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.imlet.2020.01.004_bib0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1471-4906(02)00013-3","article-title":"IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation","volume":"24","author":"Kaplanski","year":"2003","journal-title":"Trends Immunol."},{"key":"10.1016\/j.imlet.2020.01.004_bib0190","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","article-title":"Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis","volume":"146","author":"Nishimura","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.imlet.2020.01.004_bib0195","doi-asserted-by":"crossref","first-page":"456","DOI":"10.7326\/0003-4819-152-7-201004060-00010","article-title":"Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis","volume":"152","author":"Whiting","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.imlet.2020.01.004_bib0200","first-page":"11","article-title":"Diagnostic accuracy of combined tests of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: a meta-analysis","volume":"32","author":"Sun","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.imlet.2020.01.004_bib0205","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/pr.114.009639","article-title":"Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases","volume":"67","author":"Siebert","year":"2015","journal-title":"Pharmacol. Rev."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247819301592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247819301592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:03:49Z","timestamp":1762250629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247819301592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":41,"alternative-id":["S0165247819301592"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2020.01.004","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitivity and specificity of Interleukin 29 in patients with rheumatoid arthritis and other rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2020.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}]}}